Chikungunya vaccine approval in Brazil: navigating through epidemiological challenges and immunisation strategies
Claudia Renata dos Santos Barros, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Svetoslav Nanev Slavov · 2026
Read Chikungunya vaccine approval in Brazil: navigating through epidemiological challenges and immunisation strategies by Claudia Renata dos Santos Barros, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Svetoslav Nanev Slavov (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427082.txt.
Description
Barros and colleagues analyze in 2026 how Brazil should deploy its newly approved chikungunya vaccine. The live-attenuated shot was authorized in 2025 against a mosquito-borne virus that causes fever and severe joint pain. They combined national case notifications with social development data to map where transmission and vulnerability overlap.
Transmission moved in cycles and expanded toward the Southeast and South, Brazil's most crowded regions, where population immunity is low. The heaviest burden, though, sits in poorer municipalities in the Northeast, where weak health services also hide cases. The authors recommend a hybrid rollout: start with high-incidence towns in the Northeast, then reach the big southeastern cities before outbreaks grow. They add that vaccine limits in high-risk groups and live surveillance must guide the campaign.
Catalog record
| CREATOR | Claudia Renata dos Santos Barros, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Svetoslav Nanev Slavov |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |